Journal of Diabetes Research最新文献

{"title":"The AGEs/RAGE Axis Contributes to Myocardial Cell Death in Type 1 Diabetic Cardiomyopathy via the ROS/NF-κB/NLRP3 Inflammasome Pathway.","authors":"Xiaoqun Li, Shujie Chen, Ke Wang, Ke Xu, Yannan Wang, Zechao Zhang, Xue Liu","doi":"10.1155/jdr/6438008","DOIUrl":"https://doi.org/10.1155/jdr/6438008","url":null,"abstract":"<p><strong>Background: </strong>Type 1 diabetes mellitus (T1DM) cardiomyopathy is a severe complication that typically follows an insidious onset and then progresses rapidly to heart failure and premature death. AGEs accumulate in the myocardium under hyperglycemic conditions and have emerged as important mediators of this diabetic complication, although the full signaling cascades engaged by AGEs remain largely unresolved. In the present study, we therefore investigated whether AGEs induce myocardial injury in T1DM via NLRP3 inflammasome activation.</p><p><strong>Methods: </strong>A T1DM mouse model was established using streptozotocin (STZ) injections, and an in vitro model was generated by treating primary neonatal mouse cardiomyocytes with AGEs. Cardiac performance and morphological changes were examined via echocardiography and histopathological staining. Expression and activation of the NLRP3 signaling cascade were evaluated by Western blotting, ELISA, and immunofluorescence. Pyroptotic cell death was assessed by SYTOX green staining, PI uptake, and lactate dehydrogenase (LDH) release assay. Correlations between whole-blood RAGE gene expression and inflammatory cytokine levels (IL-1β and IL-18) in T1DM patients, along with myocardial abundance of RAGE, NLRP3, and N-GSDMD in the experimental mice, were analyzed as exploratory descriptive observations.</p><p><strong>Results: </strong>STZ-induced T1DM mice exhibited sustained hyperglycemia (fasting blood glucose ≥ 11.1 mmol/L) and impaired cardiac function. Myocardial tissue from T1DM animals showed marked engagement of the NLRP3 signaling cascade, as evidenced by elevated NLRP3, cleaved caspase-1 P20, and N-GSDMD, enhanced ASC speck formation, and increased serum IL-1β levels. In vitro, AGEs treatment directly triggered the NLRP3 pathway and drove cardiomyocyte pyroptosis. Mechanistically, AGEs binding to RAGE triggered a burst of intracellular ROS, which led to NF-κB activation and subsequent NLRP3 activation. These effects were suppressed by either the RAGE inhibitor FPS-ZM1 or the ROS scavenger N-acetylcysteine (NAC). Furthermore, MCC950 treatment significantly attenuated AGE-induced caspase-1 activation, IL-1β/IL-18 secretion, and N-GSDMD expression, confirming that NLRP3 is a necessary mediator of this signaling cascade. SYTOX green staining, PI uptake, and LDH release assays further demonstrated that AGE-induced pyroptotic cell death was blocked by FPS-ZM1, NAC, and MCC950, indicating that pyroptosis occurs specifically through the RAGE/ROS/NLRP3 axis. Correlation analyses revealed that RAGE transcript levels in whole blood from T1DM patients positively correlated with circulating IL-1β and IL-18. In the diabetic mouse heart, RAGE, NLRP3, and N-GSDMD protein levels were analyzed as exploratory descriptive observations and showed a consistent pattern of coexpression at the individual level.</p><p><strong>Conclusion: </strong>AGEs promote NLRP3 inflammasome activation in cardiomyocytes vi","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149268588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qinggan Mingshi Granules Inhibited Ferroptosis to Treat Diabetic Retinopathy in Mice Through NRF2/GPX4 Axis.","authors":"Zhongyong Zhang, Qianqian Jin, Hongmin Zhao, Yingkai Liu, Meng Wang, Zhongqian Han, Jin Wu, Shuquan Lv, Xiaoyun Wang, Wei Chen, Qingjin Wang, Hailong Bai, Yuansong Wang","doi":"10.1155/jdr/9978155","DOIUrl":"https://doi.org/10.1155/jdr/9978155","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy (DR) is a common microvascular complication of diabetes, which seriously affected the life quality in diabetic patients. Developing novel therapy to improve DR is essential. Qinggan Mingshi granules (QGMS) have been demonstrated with protective effects on DR clinically. However, the mechanisms of QGMS remain unclear.</p><p><strong>Method: </strong>In order to more thoroughly investigate the mechanism underlying the positive effects of QGMS on DR, a mouse model of DR was established in this study, and the positive effects of QGMS on the DR mice were observed. Next, the effects of QGMS on ferroptosis and the NRF2/GPX4 axis were investigated. In addition, we used an NRF2 inhibitor to determine whether QGMS inhibits ferroptosis in DR mice via the NRF2/GPX4 axis.</p><p><strong>Result: </strong>Our results revealed the therapeutic effects of QGMS on DR including improving the permeability of blood-retina barrier (BRB), reducing the pathological changes and ferroptosis in retina. QGMS also induced the expression of NRF2/GPX4 axis in retina. Furthermore, ML385, an NRF2 inhibitor, abolished the effects of QGMS on DR.</p><p><strong>Conclusion: </strong>This study revealed that QGMS can effectively treat DR by alleviating retinal damage through enhancing the expression of NRF2/GPX4 axis-related proteins and thus scavenging of LPOs, ultimately reducing ferroptosis.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9978155"},"PeriodicalIF":3.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study.","authors":"Miaoguan Peng, Yijuan Xie, Naifeng Liang, Shiyun Wen, Yaojie Zhai, Yingjun Xie, Yuyi Chen","doi":"10.1155/jdr/9957473","DOIUrl":"10.1155/jdr/9957473","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the effects of insulin pump intensive therapy alone with those of insulin pump intensive therapy combined with metformin or dapagliflozin on the time to achieve glycemic targets, total insulin dose at the end of intensive therapy, and pancreatic function. The study aimed to understand the impact of adding the traditional antidiabetic drug metformin and the novel antidiabetic drug dapagliflozin to routine intensive insulin therapy on treatment outcomes.</p><p><strong>Methods: </strong>A total of 110 patients with newly diagnosed T2DM (with glycated hemoglobin >9%, fasting blood glucose >11.1 mmol/L, or obvious symptoms of hyperglycemia) were enrolled in a single-center randomized controlled trial. Patients were randomized into three groups. The final analysis included 81 participants (73.6% of the enrolled) with complete data for the primary outcomes, distributed as follows: Group 1 (insulin only, n = 25), Group 2 (insulin plus dapagliflozin, n = 20), and Group 3 (insulin plus metformin, n = 36). The term \"newly diagnosed\" was defined as a diagnosis confirmed within 1 year prior to enrollment, in accordance with the Chinese guidelines for the prevention and treatment of T2DM. All patients were either treatment-naïve or had not received any sustained glucose-lowering pharmacotherapy for more than 2 weeks since diagnosis. The primary outcomes were the time to achieve glycemic targets, total insulin dose at the end of intensive therapy, and pancreatic function.</p><p><strong>Results: </strong>The fasting insulin levels in all the treatment groups changed over time, with greater decreases observed in the insulin pump therapy alone group and the insulin pump therapy + dapagliflozin group than in the insulin pump therapy + metformin group.</p><p><strong>Conclusion: </strong>These findings suggest that compared with metformin, dapagliflozin combined with intensive insulin pump therapy holds greater promise for optimizing glycaemic control in patients with T2DM, thus providing a more promising option for clinical practice.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9957473"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of Anti-Atherosclerosis Targets of Ce-Bai-Si-Wei Decoction Based on Multidimensional Data and Study on Cellular Distribution.","authors":"Wanlu Sheng, Lina Dai, Chengyao Wang, Lun Zhu, Panlei Jia, Xi Yang, Wei Huang, Yuheng Ma, Yingqi Xu","doi":"10.1155/jdr/9699723","DOIUrl":"10.1155/jdr/9699723","url":null,"abstract":"<p><strong>Background: </strong>Atherosclerosis (AS), which causes chronic inflammation, aberrant lipid metabolism and vascular endothelial damage, is the main cause of cardiovascular disease. The Ce-Bai-Si-Wei decoction (CSD) may reduce AS, although its molecular mechanisms are unknown. This study investigates core molecular pathways using multi-omics integration and experimental validation.</p><p><strong>Method: </strong>Network pharmacology prediction: Construct a 'drug-component-target-disease' interaction network using databases like TCMSP, HIT and ETCM to identify active components and targets of CSD. AS regulatory targets and signalling pathways can be identified by integrating microarray data and single-cell transcriptomics data. In vitro validation: Utilise the OX-LDL-induced model of macrophage foam cells to test CSD's effects on lipid accumulation utilising CCK-8, Oil Red O and TC/TG quantification. Validate CSD's regulatory effects on core targets using molecular docking, molecular dynamics simulation, RT-qPCR and Western blot.</p><p><strong>Results: </strong>Four core genes, HMOX1, SELE, CD4 and FLT1, were identified as key regulators of inflammation and oxidative stress in AS, and they bind stably to the active components of CSD. Single-cell data analysis suggested that CSD may improve AS by targeting macrophages and endothelial cells. In vitro, CSD reduced ox-LDL-induced lipid accumulation in macrophages and downregulated TNF-α and IL-1β. Mechanistically, the anti-AS effect of CSD depends on the NRF2/HMOX1 pathway. CSD also downregulated FLT1 and SELE in damaged endothelial cells.</p><p><strong>Conclusion: </strong>This study investigated the mechanism of CSD in treating AS. CSD acts on the core targets HMOX1, SELE, FLT1 and CD4, with macrophages and endothelial cells as key effector cells. It exerts anti-AS effects by inhibiting inflammation, reducing lipid accumulation and protecting endothelial function.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9699723"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: The Dynamics of Type 2 Diabetes Mellitus Prevalence and Management Rates among Rural Population in Henan Province, China.","authors":"Journal Of Diabetes Research","doi":"10.1155/jdr/9804834","DOIUrl":"https://doi.org/10.1155/jdr/9804834","url":null,"abstract":"","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9804834"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13491146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Qualitative Exploration of the Support Needs of Individuals With Type 2 Diabetes and Disordered Eating Behaviours.","authors":"Emma Reid, Talitha Best, Alicia Carter, Melissa Oxlad","doi":"10.1155/jdr/7718760","DOIUrl":"10.1155/jdr/7718760","url":null,"abstract":"<p><strong>Aims: </strong>We aim to explore the support needs of individuals living with type 2 diabetes and disordered eating behaviours.</p><p><strong>Methods: </strong>We conducted semistructured interviews with adult participants living with type 2 diabetes and self-identified disordered eating behaviours recruited from an Australian allied health service. Data were analysed through reflective thematic analysis.</p><p><strong>Results: </strong>Ten adults with type 2 diabetes (seven female, three male; mean age 66.3 ± 8.97, range: 52-80) were interviewed. Four themes are presented related to participants' support needs: (1) the need for increased information about the interactions between food, eating behaviours and diabetes and self-management; (2) a desire for increased time with knowledgeable health professionals who provide tailored person-centred diabetes care and support; (3) mental health services integrated into diabetes care are desired due to relationships between mental health, disordered eating behaviours and diabetes management; and (4) family, peers and community can offer invaluable support, but stigma can be a barrier to support seeking.</p><p><strong>Conclusions: </strong>Individuals living with T2DM and disordered eating behaviours report diverse support needs including tailored informational support and emotional support from health professionals, family and peers. Although further research is required to develop and evaluate the implementation of specific interventions and care pathways, health professionals should endeavour to provide adequate time and resources for personalised education, and to promote and facilitate appropriate mental health and peer supports.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e7718760"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression.","authors":"Yuxin Wang, Pei Sheng, Xue Wang, Min Lin, Wentao Cai, Shiyao Wei, Yuyun Du, Ming Yan, Lei Wang, Xiaofei An","doi":"10.1155/jdr/4391252","DOIUrl":"10.1155/jdr/4391252","url":null,"abstract":"<p><strong>Context: </strong>Qiling Hushen Formula (QLHSF) has been widely used in clinical treatment for Type 2 diabetic kidney disease (T2DKD), yet its mechanism remains unclear.</p><p><strong>Objective: </strong>This study is aimed at elucidating the protective effects and mechanisms of QLHSF on T2DKD mice.</p><p><strong>Methods: </strong>Chemical components of QLHSF were analyzed via ultraperformance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-QTOF-MS/MS). After 6 weeks of QLHSF intervention in C57BL/KSJ db/db mice, urine and serum samples were collected to measure biochemical parameters, inflammatory cytokines, and lipopolysaccharide (LPS) levels. Renal and colonic tissues were sectioned and subjected to histopathological staining. To evaluate the diversity and abundance of the gut microbiota, its composition was determined through 16S rRNA gene sequencing. Expression levels of colonic tight junction proteins, along with key proteins involved in the renal TLR4/NF-κB signaling pathway and NLRP3 inflammasome activation, were measured.</p><p><strong>Results: </strong>QLHSF decreased proteinuria and improved renal function in T2DKD mice. Renal pathological injuries and intestinal barrier destruction were also alleviated. Analysis of 16S rRNA sequencing data demonstrated that QLHSF significantly modulated the gut microbiota composition, enriching beneficial bacteria such as g_Bacteroides, g_Lachnospiraceae_NK4A136_group, g_Alistipes, g_Muribaculum, g_Odoribacter, and g_Lachnoclostridium. QLHSF treatment led to a reduction in serum LPS levels and inhibition of the renal TLR4/NF-κB/NLRP3 signaling pathway, leading to reduced inflammatory cytokine production.</p><p><strong>Conclusions: </strong>In T2DKD mice, QLHSF ameliorated proteinuria and renal injury through modulation of the gut microbiota, preservation of intestinal barrier integrity, and inhibition of the renal TLR4/NF-κB/NLRP3 pathway. These findings elucidate the pharmacological mechanism of QLHSF and provide strong experimental support for its clinical application in the treatment of T2DKD.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e4391252"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Health Outcomes in Individuals With Confirmed Versus Unconfirmed Undiagnosed Diabetes Based on Oral Glucose Tolerance Test: Findings From the Tehran Lipid and Glucose Study.","authors":"Navid Ebrahimi, Samaneh Asgari, Maryam Tohidi, Davood Khalili, Fereidoun Azizi, Sepideh Besarat, Farzad Hadaegh","doi":"10.1155/jdr/4228661","DOIUrl":"10.1155/jdr/4228661","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the prognostic performance of the single-sample confirmatory definition of undiagnosed diabetes on outcomes, including hypertension, chronic kidney disease (CKD), cardiovascular disease (CVD), and mortality, in the Tehran Lipid and Glucose Study cohort.</p><p><strong>Methods: </strong>Among 6712 participants (3682 women) aged ≥ 30 years not on glucose-lowering medication, unconfirmed undiagnosed diabetes was defined as either fasting plasma glucose (FPG) ≥ 7 mmol/L or 2-h postload glucose (2-h PG) ≥ 11.1 mmol/L, whereas confirmed undiagnosed diabetes required both. Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for each outcome.</p><p><strong>Results: </strong>At baseline, 3.6% and 3.3% of participants had confirmed or unconfirmed undiagnosed diabetes, respectively. During a median follow-up of over 10 years, both unconfirmed and confirmed undiagnosed diabetes were associated with a higher risk of developing treated diabetes, with HRs (95% CI) of 7.73 (6.35-9.44) and 17.30 (14.32-20.83), respectively. Confirmed undiagnosed diabetes was further associated with incident CKD (1.33 [1.02-1.73]), hypertension (1.26 [1.00-1.60]), first CVD (1.40 [1.01-1.93]), and hard CVD (1.65 [1.04-2.61]), whereas the association with all-cause mortality did not reach statistical significance (1.50 [0.96-2.33], p = 0.07). Unconfirmed undiagnosed diabetes was only associated with treated diabetes and first CVD (1.53 [1.11-2.12]). Isolated FPG and 2-h PG elevations showed similar risks for treated diabetes (9.00 [6.26-13.00] and 7.40 [5.92-9.24], respectively), but only isolated FPG was significantly associated with first CVD (2.55 [1.50-4.31]) and hard CVD (2.43 [1.06-6.00]), comparable with confirmed undiagnosed diabetes.</p><p><strong>Conclusions: </strong>Confirmed undiagnosed diabetes was associated with a higher risk of cardiovascular and renal outcomes. The unconfirmed undiagnosed phenotype shared a similar CVD risk with confirmed diabetes but had a 50% lower risk of treated diabetes, with a stronger association observed for isolated FPG elevation than for isolated 2-h PG.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e4228661"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose-Responsive PEGDA-GelMA-MPBA Hydrogel Loaded with Exosomes Promotes Diabetic Wound Healing.","authors":"Weiyan Yuan, Qiuru Zhuang, Qian Liu, Zhier Lin, Jiaqi Bu, Yumin Zhuo, Yijing Zhou, Xiaoying Yan, Jing Zheng","doi":"10.1155/jdr/3449648","DOIUrl":"10.1155/jdr/3449648","url":null,"abstract":"<p><p>Diabetic wound healing is frequently impaired by microcirculatory deficiencies and a proinflammatory microenvironment under conditions of persistent hyperglycemia. This study presents a smart multifunctional hydrogel dressing based on a ternary-network system of poly(ethylene glycol) diacrylate (PEGDA), gelatin methacryloyl (GelMA), and 3-methacrylamidophenylboronic acid (MPBA) for sustained delivery of exosomes. The resulting PEGDA-GelMA-MPBA@Exos (P-G-M@Exos) hydrogel exhibits high hydrophilicity, tunable mechanical strength, potent antibacterial activity, and favorable biocompatibility. A key innovation of this system is its glucose-mediated exosome release through dynamic boronate ester bonds, enabling on demand delivery of bioactive molecules in response to hyperglycemic conditions. In vivo, the hydrogel significantly enhanced M2 macrophage polarization, mitigated excessive inflammation, and promoted functional angiogenesis by upregulating VEGF. These coordinated action ultimately facilitated rapid wound closure, enhanced collagen remodeling, and promoted re-epithelialization. Our study offers a promising therapeutic platform for intelligent wound management, demonstrating strong translational potential for diabetic wound care.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e3449648"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13150340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.","authors":"Zhenhan Li, Jun Huang, Sha Zhou, Yongan Luan, Huang Xie, Zhongpei Chen, Juan Xu, Jun Qian","doi":"10.1155/jdr/8893769","DOIUrl":"10.1155/jdr/8893769","url":null,"abstract":"<p><p>GLP-1 receptor agonists (GLP-1RAs) are extensively used in treating Type 2 diabetes due to their therapeutic benefits. However, clinical reports have highlighted adverse events, particularly the underexplored association with tumor development. This study investigates GLP-1RA-related adverse events, focusing on tumorigenic risks, using data from the FDA Adverse Event Reporting System (FAERS). FAERS data from Q1 2005 to Q4 2023 were analyzed using the proportional reporting ratio (PRR) method to identify GLP-1RA-associated adverse events. Detailed analyses examined event distribution across genders, ages, and body weights, with an emphasis on tumor-related risks in vulnerable subpopulations. A total of 195,250 GLP-1RA-related adverse event reports were identified, spanning 25 system organ classes (SOCs). The most reported SOCs were gastrointestinal disorders (n = 110,451, PRR 2.44), investigative findings (n = 80,126, PRR 2.46), and metabolism and nutrition disorders (n = 25,236, PRR 2.21). Notably, 7457 cases involved benign, malignant, and unspecified tumors (PRR 0.5). Further analysis revealed that the risk of GLP-1RA-associated tumorigenesis varied by age, sex, and weight, suggesting that tumorigenesis risk differed in specific subpopulations. These findings underscore the need for vigilance regarding GLP-1RA-related adverse events, particularly tumor risks in specific subgroups. Clinicians should consider patient-specific factors, such as age, gender, and body weight, to ensure safe and effective GLP-1RAs therapy.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e8893769"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147491289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}